| Date | Title | Description |
| 31.03.2026 | Enzymatica and STADA sign partnership agreement for Germany and Austria | Enzymatica and STADA sign partnership agreement for Germany and Austria
Tue, Mar 31, 2026 14:00 CET Report this content
Regulatory press release
• The new partnership agreement covers the launch and distribution of Enzymatica’s ColdZyme® te... |
| 18.02.2026 | Year-end report 2025: New CEO takes the helm – initiates the next phase of Enzymatica’s international expansion | Year-end report 2025: New CEO takes the helm – initiates the next phase of Enzymatica’s international expansion
Wed, Feb 18, 2026 08:30 CET Report this content
Fourth quarter January-December
Net sales reached SEK 18.3 (17.2) million The op... |
| 30.10.2025 | Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion | Quarterly report Q3/2025: Strong development in Sweden and continued focus on international expansion
Thu, Oct 30, 2025 08:30 CET Report this content
Third quarter January-September
Net sales reached SEK 15,0 (12,6) million. The operating r... |
| 22.08.2025 | Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 August 2025 | Bulletin from the Extraordinary General Meeting of Enzymatica AB (publ) on 22 August 2025
Fri, Aug 22, 2025 13:50 CET Report this content
On 22 August 2025, the shareholders of Enzymatica AB (publ) (the “Company”) held an Extraordinary Gene... |
| 12.08.2025 | Sana Alajmovic appointed new CEO of Enzymatica AB | Sana Alajmovic appointed new CEO of Enzymatica AB
Tue, Aug 12, 2025 08:00 CET Report this content
The Board of Directors of Enzymatica AB (publ) has appointed Sana Alajmovic as the new Chief Executive Officer. She succeeds Claus Egstrand, w... |
| 06.08.2025 | Notice of Extraordinary General Meeting in Enzymatica AB (publ) | Notice of Extraordinary General Meeting in Enzymatica AB (publ)
Wed, Aug 06, 2025 08:30 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation... |
| 17.07.2025 | Quarterly report Q2/2025: Strong development in Sweden and increased international activity | Quarterly report Q2/2025: Strong development in Sweden and increased international activity
Thu, Jul 17, 2025 08:30 CET Report this content
Second quarter January-June
Net sales reached SEK 8.3 (6.4) million. The operating result totaled SE... |
| 01.07.2025 | Leadership Shakeup at Enzymatica: A New Chapter Begins | Enzymatica AB is at a crossroads. The company, known for its innovative cold remedy, ColdZyme®, is undergoing significant leadership changes. The recent announcements of Claus Egstrand stepping down as CEO and Therese Filmersson leaving her... |
| 30.06.2025 | Enzymatica’s CFO Therese Filmersson to leave her position | Enzymatica’s CFO Therese Filmersson to leave her position
Mon, Jun 30, 2025 08:15 CET Report this content
Enzymatica AB (publ) announces today that the company’s Chief Financial Officer (CFO), Therese Filmersson, has decided to leave her po... |
| 26.06.2025 | Claus Egstrand steps down as CEO of Enzymatica | Claus Egstrand steps down as CEO of Enzymatica
Thu, Jun 26, 2025 12:15 CET Report this content
The CEO of Enzymatica AB, Claus Egstrand, is stepping down from his role and will join the company’s Board of Directors. Recruitment of a new CEO... |
| 08.05.2025 | Enzymatica and Cereno Scientific: A Glimpse into the Future of Biotech | In the bustling world of biotechnology, two companies are making waves: Enzymatica AB and Cereno Scientific. Both are charting paths through the complex landscape of health and wellness, each with unique strategies and visions. Their recent... |
| 07.05.2025 | Bulletin from the annual general meeting of Enzymatica AB (publ) on May 7, 2025 | Bulletin from the annual general meeting of Enzymatica AB (publ) on May 7, 2025
Wed, May 07, 2025 15:44 CET Report this content
Enzymatica AB (publ) held its annual general meeting on May 7, 2024. At the annual general meeting, the followin... |
| 29.04.2025 | Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion | Quarterly report Q1/2025: Enzymatica strengthens its position in home markets and focuses on international expansion
Tue, Apr 29, 2025 08:30 CET Report this content
First quarter Net sales amounted to SEK 12.3 million (9.4). Operating resul... |
| 02.04.2025 | Notice of Annual General Meeting 2025 in Enzymatica AB (publ) | Notice of Annual General Meeting 2025 in Enzymatica AB (publ)
Wed, Apr 02, 2025 14:45 CET Report this content
The annual general meeting of Enzymatica AB (publ), reg. no. 556719-9244, will be held on 7 May 2025 at 14:30 CEST, Elite Hotel Id... |
| 11.03.2025 | BioStock: Enzymatica's results published in The Journal of Physiology | BioStock: Enzymatica's results published in The Journal of Physiology
Tue, Mar 11, 2025 08:15 CET Report this content
Study results show that Enzymatica’s mouth spray, ColdZyme, reduces viral load and inhibits its spread, leading to fewer s... |
| 08.03.2025 | Svenska Aerogel's Rights Issue: A Strategic Move for Growth | Svenska Aerogel Holding AB is gearing up for a significant financial maneuver. The company has announced a rights issue, a strategic step to bolster its capital and fuel growth. This move is akin to planting seeds in fertile soil, hoping fo... |
| 06.03.2025 | Replay Link to Digital Press Briefing – March 5, 2025 | Replay Link to Digital Press Briefing – March 5, 2025
Thu, Mar 06, 2025 12:02 CET Report this content
In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB held a digital press confer... |
| 28.02.2025 | Invitation to Press Briefing – 5 March 2025 | Invitation to Press Briefing – 5 March 2025
Fri, Feb 28, 2025 17:30 CET Report this content
In connection with the publication of results from two independent research studies on ColdZyme, Enzymatica AB invites to a digital press briefing o... |
| 28.02.2025 | New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms | New independent studies show that ColdZyme addresses the root cause of respiratory infections, reducing sick days and symptoms
Fri, Feb 28, 2025 16:00 CET Report this content
Today, results from two independent studies on the medical device... |
| 25.02.2025 | BioStock: Enzymatica boosts Q4 revenue but sees room for stronger partner sales | BioStock: Enzymatica boosts Q4 revenue but sees room for stronger partner sales
Tue, Feb 25, 2025 09:27 CET Report this content
The cold season is in full swing, which is also reflected in Enzymatica’s fourth-quarter report, showing increas... |
| 18.02.2025 | Year-end report 2024: Strong performance in core markets – preparing for international growth | Year-end report 2024: Strong performance in core markets – preparing for international growth
Tue, Feb 18, 2025 08:30 CET Report this content
Fourth quarter January-December
Net sales reached SEK 17.2 million (15.8). The operating result to... |
| 05.09.2024 | Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load | Reported results on secondary endpoints from the University of Kent study on ColdZyme® show significant reduction of symptoms, lost training days and viral load
Thu, Sep 05, 2024 20:30 CET Report this content
The study, which has now been c... |
| 16.08.2024 | Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days. | Final results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days.
Fri, Aug 16, 2024 15:30 CET Report this content
The University of Kent has published final results for the Primary Endpoint... |
| 13.06.2024 | Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days | Interim results from independent clinical study of ColdZyme® show duration of illness lowered by approximately 5 days
Thu, Jun 13, 2024 16:50 CET Report this content
University of Kent has earlier this afternoon published interim results fr... |
| 25.04.2024 | Interim report Q1/2024: MDR certification opens up great commercial opportunities | Interim report Q1/2024: MDR certification opens up great commercial opportunities
Thu, Apr 25, 2024 08:30 CET Report this content
First quarter Net sales reached SEK 9.4 (13.0) million. The operating result totaled SEK -18.4 (-14.4) million... |
| 09.04.2024 | Enzymatica publishes annual report for 2023 | Enzymatica publishes annual report for 2023
Tue, Apr 09, 2024 08:30 CET Report this content
The annual report for Enzymatica 2023 was published today (in Swedish) on the company’s website: Finansiella rapporter - Enzymatica. The annual repo... |
| 27.03.2024 | Notice of Annual General Meeting 2024 in Enzymatica AB (publ) | Notice of Annual General Meeting 2024 in Enzymatica AB (publ)
Wed, Mar 27, 2024 19:45 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, ... |
| 19.02.2024 | Enzymatica publishes information memorandum about rights issue of shares | Enzymatica publishes information memorandum about rights issue of shares
Mon, Feb 19, 2024 16:00 CET Report this content
NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, RUSSIA, HONGKONG, ... |
| 16.02.2024 | Year-end report 2023: Scientific and regulatory progress generating international interest | Year-end report 2023: Scientific and regulatory progress generating international interest
Fri, Feb 16, 2024 08:30 CET Report this content
Fourth quarter January-December
Net sales reached SEK 15.8 (16.6) million. The operating result total... |
| 07.11.2023 | Interim report Q3/2023: Research results that reshape the competitive landscape | Interim report Q3/2023: Research results that reshape the competitive landscape
Tue, Nov 07, 2023 08:30 CET Report this content
Third quarter January-September
Net sales reached SEK 13.3 (18.5) million. The operating result totaled SEK -8.7... |
| 18.07.2023 | Interim report Q2/2023: An exciting and important time ahead | Interim report Q2/2023: An exciting and important time ahead
Tue, Jul 18, 2023 08:30 CET Report this content
Q2 H1
Net sales reached SEK 8.8 (9.6) million. The operating result totaled SEK -11.2 (-15.9) million. Earnings per share, basic an... |
| 04.05.2023 | Bulletin from Annual General Meeting of Enzymatica AB (publ) | Bulletin from Annual General Meeting of Enzymatica AB (publ)
Thu, May 04, 2023 16:00 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, t... |
| 27.04.2023 | Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan | Interim report Q1/2023: Strong start to the year – Enzymatica’s growth journey continues according to plan
Thu, Apr 27, 2023 08:30 CET Report this content
First quarter
Net sales reached SEK 13.0 (4.2) million. The operating result totaled ... |
| 31.03.2023 | Notice of Annual General Meeting 2023 in Enzymatica AB (publ) | Notice of Annual General Meeting 2023 in Enzymatica AB (publ)
Fri, Mar 31, 2023 13:40 CET Report this content
The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, ... |
| 17.02.2023 | Interim report Q4/2022: A year that laid the foundation for growth | Interim report Q4/2022: A year that laid the foundation for growth
Fri, Feb 17, 2023 08:30 CET Report this content
Significant events during the quarter Significant events after the quarter
On October 31, the journal Respiratory Research pu... |
| 02.11.2022 | Interim report Q3/2022: A broader role for ColdZyme adds potential for the future | Interim report Q3/2022: A broader role for ColdZyme adds potential for the future
Wed, Nov 02, 2022 08:30 CET Report this content
Significant events during the quarter Significant events after the quarter
To ensure the long-term financing o... |
| 19.07.2022 | Interim report Q2/2022: Improved sales give confidence for the future | Interim report Q2/2022: Improved sales give confidence for the future
Tue, Jul 19, 2022 08:30 CET Report this content
Significant events in Q2 Significant events after the quarter
In June, Enzymatica AB signed a loan agreement with the thre... |
| 28.04.2022 | Interim report Q1/2022: Our financial targets remain in place | Interim report Q1/2022: Our financial targets remain in place
Thu, Apr 28, 2022 08:30 CET Report this content
Significant events in Q1 Significant events after the quarter
In March, Enzymatica announced that its mouth spray would be launche... |
| 17.02.2022 | Year-end report: Clear signs of favourable market trends after a challenging 2021 | Year-end report: Clear signs of favourable market trends after a challenging 2021
Thu, Feb 17, 2022 08:30 CET Report this content
Significant events in Q4 Other events in Q4
The Extraordinary General Meeting on October 18, 2021, resolved to... |
| 12.01.2022 | Enzymatica comments on wrongful wording in Dagens Medicin | Enzymatica comments on wrongful wording in Dagens Medicin Wed, Jan 12, 2022 14:35 CET
The headline and introduction of an article today on the webpage of the Swedish magazine Dagens Medicin wrongfully claim that a study on ColdZyme® has bee... |
| 02.11.2021 | Interim Report Q3 | Interim Report Q3
January-September 2021
Enzymatica AB is a life science company that develops and sells health products mainly to treat upper respiratory diseases and symptoms. The products are based on a barrier technology that includes m... |
| 02.11.2021 | The long-term plan remains in challenging times | The long-term plan remains in challenging times Tue, Nov 02, 2021 08:50 CET
INTERIM REPORT JANUARY-SEPTEMBER 2021:
Significant events in Q3 Significant events after the quarter
The Chinese and US patent offices gave advance notice of their ... |
| 29.09.2021 | Notice of extraordinary general meeting in Enzymatica AB (publ) | Notice of extraordinary general meeting in Enzymatica AB (publ) Wed, Sep 29, 2021 16:50 CET
The shareholders in Enzymatica AB (publ), Reg. No. 556719-9244, are hereby invited to the extraordinary general meeting (Sw. extra bolagsstämma) to ... |
| 08.09.2021 | Claus Egstrand takes office as CEO ahead of schedule | Claus Egstrand takes office as CEO ahead of schedule Wed, Sep 08, 2021 11:00 CET
Claus Egstrand assumes his role as CEO of Enzymatica three months ahead of schedule and takes office on September 9, 2021.
When Claus Egstrand was appointed ne... |
| 11.08.2021 | Chinese and US patent authorities issue notices of allowance for patent for key component in cold spray ColdZyme | Chinese and US patent authorities issue notices of allowance for patent for key component in cold spray ColdZyme Wed, Aug 11, 2021 10:00 CET
According to notices from patent authorities in China respectively USA, Enzymatica will be granted ... |
| 16.07.2021 | Enzymatica : Interim Report January - June 2021 | INTERIM REPORT FOR
ENZYMATICA AB (PUBL)
JANUARY-JUNE 2021
Continued lower sales due to pandemic but some stabilization
Q2
Net sales reached SEK 6.1 (13.9) million.
Result after tax came in at SEK -19.7(-11.7) million.
Earnings per share, ba... |
| 16.07.2021 | Continued lower sales due to pandemic but some stabilization | Continued lower sales due to pandemic but some stabilization Fri, Jul 16, 2021 08:30 CET
Q2 Net sales reached SEK 6.1 (13.9) million. Result after tax came in at SEK -19.7 (-11.7) million. Earnings per share, basic and diluted, were SEK -0.... |
| 12.07.2021 | Enzymatica and STADA extend agreement on ViruProtect to Vietnam | Enzymatica and STADA extend agreement on ViruProtect to Vietnam Mon, Jul 12, 2021 15:00 CET
Enzymatica has licensed to STADA exclusive rights to market and sell ViruProtect® (ColdZyme®) in Vietnam. The agreement builds on the two companies’... |
| 07.06.2021 | Enzymatica announces outcome of new rights issue | Enzymatica announces outcome of new rights issue Mon, Jun 07, 2021 17:08 CET
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, SINGAPORE, THE UNI... |
| 03.06.2021 | Enzymatica launches ColdZyme on Amazon | Enzymatica launches ColdZyme on Amazon Thu, Jun 03, 2021 14:45 CET
Enzymatica now launches its common cold spray ColdZyme on Amazon in the UK and Sweden. The E-commerce for health care products has increased during the past years, and in pa... |
| 21.05.2021 | Patent for ColdZyme approved in Japan | Patent for ColdZyme approved in Japan Fri, May 21, 2021 08:30 CET
The Japanese patent authority has granted Enzymatica’s patent for the cod enzyme that is a key component of Enzymatica’s cold spray ColdZyme® for the Japanese market. The pat... |
| 31.03.2021 | ENZYMATICA AB
Enzymatica : Publication of the Annual Report 2020 | Enzymatica announces today that the annual report 2020 is available on the company's web site www.enzymatica.se. The annual report is produced in Swedish. A brief English version of the annual report is available on the English version of t... |
| 31.03.2021 | Enzymatica Publication of the Annual Report 2020 | Enzymatica Publication of the Annual Report 2020 Wed, Mar 31, 2021 09:00 CET
Enzymatica announces today that the annual report 2020 is available on the company's web site www.enzymatica.se. The annual report is produced in Swedish. A brief ... |
